Empagliflozin/Metformin/Sitagliptin (Overseas Pharmaceuticals)

恩格列净/二甲双胍/西格列汀 (越洋医药)

Report date: 2026/05/22 20:01:29

Base Information

Drug NameEmpagliflozin/Metformin/Sitagliptin (Overseas Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsDipeptidyl peptidase IV inhibitors
TargetsSodium/glucose cotransporter 2Protein kinase AMP-activated non-catalytic subunit beta 1Dipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTaizhou Overseas Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaizhou Overseas Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A